Mild cognitive impairment of uncertain or unknown etiology describes a situation where a person’s thinking and memory have measurably declined beyond what’s expected for their age, but clinicians cannot pin down a specific disease causing it. This is far more common than most people realize. MCI itself is a clinical syndrome, not a single disease, and a substantial share of people who receive the label leave the clinic without a clear explanation for why their cognition is slipping. The reasons for that diagnostic limbo range from genuine medical mystery to the limits of current testing, and understanding them matters for what comes next.
Why the Cause So Often Stays Unclear
MCI was originally defined with Alzheimer’s disease in mind. Early criteria focused on memory complaints and assumed that most people with MCI were on the road to Alzheimer’s. Over time, researchers recognized that many people with cognitive decline didn’t fit that mold, and the definition expanded to include non-memory problems like trouble with language, attention, or planning. But even with broader criteria, the diagnosis remains surprisingly unstandardized. A review of nine incidence studies conducted across North America, South America, and Europe found that although each study used similar diagnostic criteria, the way those criteria were applied varied considerably. Some studies required the patient to report their own cognitive complaints; others didn’t. Impairment thresholds differed too, with some studies setting the cutoff at 1.5 standard deviations below average, others at 1.0, and still others at the 10th percentile. The result was incidence estimates ranging from roughly 9 to 77 per 1,000 person-years, a nearly tenfold spread.1ScienceDirect. Mild cognitive impairment: a history and the state of current diagnostic criteria
That variation has a direct consequence for you if you’re diagnosed: depending on which clinic you visit, how the neuropsychologist scores your tests, and which threshold they use, you might or might not qualify for MCI at all. And if you do qualify, the investigation into why your cognition has changed depends heavily on which biomarkers are available at your center. Many community clinics lack access to amyloid PET scans or spinal fluid analysis, which means the underlying pathology simply cannot be identified with the tools at hand. The “unknown etiology” label in those cases often reflects the limits of local resources as much as the limits of medical knowledge.
Neurodegenerative Diseases That Mimic or Overlap With Alzheimer’s
When people think of MCI, they usually think of early Alzheimer’s. But several other brain diseases cause very similar symptoms and are only now being recognized in living patients. These conditions explain a meaningful fraction of MCI cases that would otherwise be labeled “unknown.”
One of the most discussed is a biomarker pattern researchers call “suspected non-Alzheimer pathophysiology,” or SNAP. These are people whose brain scans show signs of neurodegeneration, like hippocampal shrinkage or reduced brain metabolism, but whose amyloid tests come back negative. In one study, about 17% of MCI patients fell into this SNAP category.2PubMed Central. Suspected non-AD pathology in mild cognitive impairment These individuals performed worse on memory tests than people with no neurodegeneration and had larger volumes of white matter damage, but their amyloid levels looked normal. Researchers have found that SNAP patients progress to dementia at rates well above people with no biomarker abnormalities, with one study reporting a hazard ratio of 2.7 compared to people who were both amyloid- and neurodegeneration-negative.3PubMed Central. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression The hippocampal atrophy in SNAP patients was actually more severe than in people who were amyloid-positive with neurodegeneration, yet the underlying cause remains debated. Cerebrovascular disease and hippocampal pathologies other than amyloid are leading suspects.
Another condition gaining recognition is limbic-predominant age-related TDP-43 encephalopathy, or LATE. This disease involves the buildup of a misfolded protein called TDP-43 in the brain’s memory regions. LATE is extremely common in people over 80 and produces a slowly progressive memory loss that looks a lot like Alzheimer’s on clinical exam.4PubMed Central. Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy Until recently, LATE could only be confirmed at autopsy, which means many people living with LATE-related MCI were told the cause of their impairment was unknown. New brain imaging techniques are beginning to change this. A study using a specific type of PET scan found that a LATE-like pattern of reduced brain metabolism in the medial temporal and limbic areas could identify a subgroup of MCI patients who were clinically and biologically distinct from those with Alzheimer’s.5PubMed Central. Clinical and molecular correlates of limbic age-related TDP-43 encephalopathy (LATE) 18F-FDG-PET pattern in amnestic mild cognitive impairment As anti-amyloid drugs enter clinical use, distinguishing LATE from Alzheimer’s is becoming more than academic. Treating a LATE patient with an amyloid-clearing drug would offer no benefit and carry real risk.
A third and related condition is primary age-related tauopathy, or PART. This involves tau tangles in the brain without significant amyloid buildup. A large study of over 1,800 community-dwelling older adults found that about 28% had PART confirmed at autopsy. When tangles extended from the hippocampus into the nearby inferior temporal cortex, the effect on cognitive decline was more than three times stronger than hippocampal tangles alone. And when LATE was also present alongside PART, its impact on decline was even greater than the tau tangles themselves.6PubMed Central. Cognitive decline in community-dwelling older persons with primary age-related tauopathy: role of anatomical location of tangles and other co-existing brain pathologies The practical takeaway is that many older adults with “unexplained” MCI may have PART, LATE, or both, layered with vascular damage and Lewy body pathology, creating a complex picture that no single diagnostic test can easily unravel.
Treatable Conditions That Can Masquerade as Mysterious MCI
Not all unclear MCI cases involve irreversible brain disease. Some of the most important causes to identify are the ones you can actually treat. Depression is one of the most common offenders. It can cause problems with concentration, memory, and processing speed that meet the clinical threshold for MCI. But depression also appears to be a genuine risk factor for future dementia and, in some cases, an early symptom of a neurodegenerative process that hasn’t fully declared itself yet. The relationship works in multiple directions: depression can cause hippocampal shrinkage, disrupt stress hormone regulation, and promote inflammation, all of which can impair cognition independently of any degenerative disease.7PubMed Central. Overlay of Late-Life Depression and Cognitive Impairment When someone with depression and MCI gets effective treatment for their mood, their cognitive scores sometimes improve substantially. Sometimes they don’t. Separating depression-induced cognitive problems from depression-as-prodrome-of-dementia is one of the genuinely hard problems in clinical neurology.
Sleep disorders are another underappreciated contributor. In a study of nearly 400 patients with obstructive sleep apnea, 38% met criteria for MCI. Severe sleep apnea, poor nighttime sleep quality, and daytime sleepiness were all associated with increased MCI risk after adjusting for other factors.8BMC Psychiatry. Relationship between sleep apnea severity and mild cognitive impairment in people with obstructive sleep apnea Someone whose MCI is driven largely by fragmented sleep and low oxygen levels at night has a fundamentally different prognosis from someone with early Alzheimer’s, yet both can present with the same memory complaints on the same office tests.
Medications deserve special attention. Many commonly prescribed drugs have anticholinergic properties, meaning they block a brain chemical involved in memory and attention. These include certain antihistamines, bladder medications, older antidepressants, and some drugs for nausea or muscle spasms. A community-based study in northern Italy found that among older adults, the odds of having MCI were about three times higher in people with a high anticholinergic medication burden. Executive function, including verbal fluency and planning, was particularly affected.9PubMed Central. Polypharmacy, drug-drug interactions, anticholinergic burden and cognitive outcomes: a snapshot from a community-dwelling sample of older men and women in northern Italy When the diagnosis is MCI of unknown cause, a thorough medication review is one of the most straightforward steps a clinician can take, and one of the most frequently overlooked.
What Happens Over Time
The trajectory of MCI is much less predictable than people assume. Not everyone gets worse. Some people remain stable for years, and some actually revert to normal cognition, especially if a treatable cause like depression, medication effects, or sleep disruption is addressed. But a substantial fraction do progress to dementia. One study that tracked 335 MCI patients over about five and a half years found that 43% converted to dementia during that period. Family history of dementia and lower baseline cognitive scores were significant predictors, as was, unexpectedly, low body temperature.10PubMed Central. Predictors of Conversion to Dementia in Patients With Mild Cognitive Impairment: The Role of Low Body Temperature
Biomarker testing, when available, can sharpen the prognosis. Among MCI patients with both amyloid and tau positivity, researchers found that baseline spinal fluid tau levels, cognitive scores, daily functioning questionnaires, and language assessments could predict whether someone would progress to dementia within two years.11PubMed Central. Amyloid and tau positive mild cognitive impairment: clinical and biomarker characteristics of dementia progression But this kind of testing is precisely what’s unavailable for people whose MCI has no identified cause. If your workup doesn’t include biomarkers, the uncertainty about your future is real, and honest clinicians will tell you so.
How Different Patterns of Impairment Offer Clues
The specific cognitive abilities affected can sometimes hint at what’s going on under the surface, even without advanced imaging. MCI is broadly divided into amnestic forms (primarily memory problems) and non-amnestic forms (problems with language, attention, spatial skills, or executive function). Research comparing these subtypes has found meaningful differences. In one study, people with primarily memory-based MCI performed worse on verbal and non-verbal memory tasks but were relatively preserved in other areas. By contrast, those with deficits across multiple domains had worse language performance, slower processing speed, and more trouble with fine motor control and visuospatial tasks.12Journal of Neurology, Neurosurgery & Psychiatry. Neuropsychological characteristics of mild cognitive impairment subgroups
These patterns matter because different diseases tend to attack different brain networks. Alzheimer’s disease typically starts with memory. Vascular disease often affects processing speed and executive function. LATE targets the medial temporal lobe. Lewy body pathology can impair attention and visuospatial skills early. When a clinician observes a non-amnestic pattern in someone whose standard workup is negative for Alzheimer’s markers, it doesn’t necessarily mean the etiology is “unknown” in the sense that nothing is wrong. It may mean the tools used to investigate were looking for the wrong disease.
The Communication Challenge
Being told you have MCI of uncertain cause puts you in an uncomfortable position. You know something is wrong, but nobody can tell you exactly what it is or what will happen next. Research into how clinicians handle these conversations reveals that the uncertainty is difficult on both sides. One study analyzing recorded clinic visits found that doctors expressed uncertainty more frequently when disclosing an MCI diagnosis compared to a cognitively normal result.13PubMed Central. Communicating uncertainties when disclosing diagnostic test results for Alzheimer’s dementia in the memory clinic: The ABIDE project When risk information was discussed at all, it was typically vague and verbal, without specific numbers or timeframes.14PLOS ONE. Clinicians’ communication with patients receiving a MCI diagnosis: The ABIDE project Clinicians tended to emphasize hopeful outcomes, which may feel reassuring in the moment but can leave patients and families without the information they need for planning.
Experts have argued that the MCI diagnosis should be used to validate concerns and to make clear that the cognitive changes are not normal aging, rather than to soften or delay a more specific diagnosis.15PubMed Central. Communicating mild cognitive impairment diagnoses with and without amyloid imaging If you’ve been told you have MCI with no clear cause, it’s reasonable to ask your clinician directly: what tests have been done, what has been ruled out, and what further evaluation might narrow the picture. You may not get a definitive answer, but you can get a clearer sense of where the uncertainty lies.
What You Can Actually Do About It
The American Academy of Neurology recommends that anyone diagnosed with MCI be monitored over time, with periodic reassessment of cognitive function.16PubMed Central. Practice guideline update summary: Mild cognitive impairment [RETIRED]: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology No drug has been proven to reliably slow progression in MCI broadly, and the newer anti-amyloid therapies are targeted specifically at Alzheimer’s pathology, which may or may not be what’s driving your symptoms. That leaves lifestyle interventions as the main actionable strategy. Management typically focuses on increasing physical and cognitive activity, controlling cardiovascular risk factors like hypertension and diabetes, and treating conditions like depression that may be worsening cognition.17PubMed Central. The Effect of Physical Exercise on Patients With Mild Cognitive Impairment: A Scoping Review
These recommendations are not groundbreaking, and they may feel unsatisfying when you’re looking for a specific answer to a specific problem. But the evidence behind them is real, and some of the benefit may come from addressing the very treatable causes discussed above. Getting a sleep study, reviewing your medications with a pharmacist or geriatrician, and treating depression are all concrete steps that can meaningfully change the trajectory of MCI for some people, particularly those whose etiology is “unknown” precisely because these contributors haven’t been evaluated.
Cognitive Reserve and Why Some People Are More Resilient
One concept that has held up across multiple studies is cognitive reserve, the idea that lifelong mental engagement builds a kind of buffer against cognitive decline. A systematic review found that higher cognitive reserve was consistently associated with a lower risk of MCI and with better cognitive functioning among people who already had it.18PubMed Central. The Protective Role of Cognitive Reserve in Mild Cognitive Impairment: A Systematic Review Education, occupational complexity, bilingualism, and social engagement all contribute to this reserve. The practical implication is that two people with the same amount of brain pathology can present very differently: one may test normally while the other meets criteria for MCI, because their cognitive reserve absorbs different amounts of damage before symptoms surface.
This also complicates the “unknown etiology” picture. A person with high cognitive reserve might not get diagnosed until the underlying disease is quite advanced, because their test scores stayed above the impairment threshold for longer. Conversely, someone with lower reserve might be flagged with MCI when the actual brain pathology is still minimal. Reserve doesn’t change what’s happening in the brain, but it changes when and how it shows up on tests, which is one more reason the cause of any individual’s MCI can be genuinely difficult to determine.
Disparities in How the Diagnosis Gets Applied
The uncertainty around MCI diagnosis doesn’t fall equally on everyone. Research examining racial differences in how MCI is identified found significant gaps between Black and White individuals assessed at Alzheimer’s Disease Centers. Among people given a clinical MCI diagnosis, White individuals were significantly more likely to also meet strict test-based criteria for MCI than Black individuals were. White individuals with MCI showed, on average, about one additional low test score compared to Black individuals with the same clinical diagnosis. Black individuals were also more likely to be classified with the non-amnestic subtype of MCI, while White individuals were more likely to receive an amnestic subtype diagnosis.19PubMed Central. Examining racial disparities in the diagnosis of mild cognitive impairment
These findings suggest that the cognitive tests used in standard evaluations may not perform the same way across all populations, raising the possibility that some people are diagnosed with MCI of uncertain cause partly because the tools being used weren’t well calibrated for them in the first place. It also means that the “unknown” in “unknown etiology” sometimes contains a structural blind spot in the diagnostic process itself, not just a gap in medical knowledge about the brain.
Digital Tools and the Future of Diagnosis
One area of active development is the use of passive digital health technologies to help resolve diagnostic ambiguity in MCI. A systematic review found that tools collecting data on gait patterns, physical activity, and even speech characteristics are being explored as continuous, objective markers that could supplement traditional once-a-year office testing.20npj Digital Medicine. Passive digital health technologies for Alzheimer’s disease screening and diagnosis The appeal is straightforward: a person’s cognitive function fluctuates day to day, and a single office visit captures only a snapshot. Wearable sensors or smartphone-based tracking could, in theory, reveal subtle patterns of decline or improvement that a yearly exam misses entirely. These technologies are still largely in the research phase, but they represent a potential shift from episodic clinic-based assessment to continuous real-world monitoring, which could be especially valuable for people whose MCI defies easy categorization.